Last reviewed · How we verify
FLU-v Control
At a glance
| Generic name | FLU-v Control |
|---|---|
| Sponsor | PepTcell Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Production and Evaluation of an Evidence-based Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases (HAV-RID Study) (NA)
- A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A (PHASE2)
- Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine (PHASE3)
- A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine (PHASE2)
- A Phase 2, Double-blind Study to Evaluate Intranasal Trivalent Influenza Virus Vaccine in Healthy Adult (PHASE2)
- Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults (PHASE2)
- Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine (PHASE1)
- A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLU-v Control CI brief — competitive landscape report
- FLU-v Control updates RSS · CI watch RSS
- PepTcell Limited portfolio CI